Meet with Johnson & Johnson Leaders – Seattle Edition, 2026
Application due by May 3rd - In-person meeting on June 2nd.
We are advancing transformative innovations in Drug Discovery, Drug Development, Data
Sciences and Digital Health, and applying it to accelerate the development of
breakthrough therapies that make a real difference. Our strategy is rooted in
understanding the biological complexity of therapeutic indications and technology
challenges to develop novel therapies tailored to distinct disease subgroups, leveraging
our deep expertise across modalities such as small molecules, multi-specific antibodies,
antibody-drug conjugates, cell therapies, and other cutting-edge platforms.
Johnson & Johnson is also focused on building external partnerships to further advance
therapeutic solutions. Thus, we are inviting visionary startups and researchers to connect
with our Leadership team and explore opportunities in:
Data science & digital health
- Foundation models (e.g., virtual disease models) and validation platforms for
uncovering novel biology and interrogating complex biological mechanisms - Computer vision and digital health tools that enable precision medicine
- Generative AI and agentic frameworks to enhance scientific reasoning & insights,
autonomously perform or orchestrate workflows and boost R&D productivity
Discovery, product development & supply
- Small Molecules: Small molecule platforms focused on oral bioavailability, targeted protein degradation (molecular glues/degrader), scalable API properties, and ultra long acting or localized drug delivery.
- siRNA: Extra hepatic siRNA delivery technologies, emphasizing brain and retinal targeting and improved endosomal escape.
- Protein Therapeutics: Multispecific conditional activating and high dose protein therapeutics enabled by improved discovery, high titer manufacturing cell lines, ultra concentrated formulations, and non IV delivery (SC, oral, intracellular).
- Cell Therapy: Scalable CAR-T platforms leveraging high throughput screening, advanced gene editing, and automated, cost efficient manufacturing; in vivo CAR-T
- In Silico Approaches: AI/ML driven de novo generation, lead optimization, virtual screening, and molecular property prediction integrated with high throughput and computationally intensive discovery workflows.
- Non Clinical Safety: Early discovery safety and PK/PD de risking using high throughput, human relevant models, non invasive in vivo endpoints, and systems pharmacology.
If your company is based in the Seattle region and is developing bold, differentiated, and
potentially transformative approaches in these areas, we would like to hear from you.
Selected applicants will be invited to present their projects directly to Johnson & Johnson’s
Leadership team.
Meet with J&J Leaders - apply to present your bold innovation and explore partnering.
Application due by: May 3rd.
Selected companies will be notified by May 18th.
In-person meeting on June 2nd. Details to be coordinated with each selected company.